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Dr G. Patrick Clagett (Dallas, Tex). This is another excellent
study from the Wake Forest group that is clinically helpful in the
management of patients with renovascular disease and hyperten-
sion. It adds another nail in the coffin of prophylactic or “drive-by”
renal artery angioplasty.
The 9% incidence of progression may actually be an overesti-
mate, given the threshold criteria of a 21 to 39 cm/second increase
over 3 years. Despite the statistical analysis to judge the variance of
this parameter, I find these criteria to be well within the variability
of repeated testing. This is especially so given the turnover in techs,
equipment, and the inherent difficulty of this non-invasive exam.
So, my first question is do you have robust measures of variability
of the peak systolic velocity with repeated measurements in pa-
tients with and without disease over time?
My second question relates to the value of follow-up renal
duplex sonography scan. If it doesn’t really help in predicting
treatable events, is it ever worthwhile to follow patients with
renovascular disease with repeated exams? If so, who do you select
for follow-up sonography scan?
My final question involves selecting patients for intervention.
Despite, the increase in morbidity and mortality, the Wake Forest
group and others have documented that surgical renal revascular-
ization in selected patients can lead to improvement in blood
pressure, renal function, and dialysis-free survival. Is this also true
for renal percutaneous transluminal renal angioplasty (PTRA)? I
must say, the data to support this are weak. Among those with
documented renovascular disease, who do you select for renal
PTRA?
Dr Davis. We acknowledge that the utilization of repeated
measurements of peak systolic velocity (PSV) to construct a regres-
sionmodel to define progression was not particularly robust. These
patients had widely varying numbers of duplex scan examinationsover the follow-up time, and our model could well be predomi-
nantly influenced by those few patients with multiple scans that did
not demonstrate significant progression.
In regards to the second question, we do feel that it is valuable
to follow patients with duplex scans and continue to do so in our
practice. We recognize that there are few data to support such
routine use of follow-up renal duplex sonography scans, however,
we do feel that its use, in conjunction with attention to renal
function and strict blood pressure control, does enable us to
predict that subset of patients with specific clinical indications for
revascularization. We do recognize that our particular clinical
interest in this disease process may influence our frequency of this
follow-up.
Regarding the third question, unfortunately, the best medical
therapy vs best medical therapy plus percutaneous intervention vs
best medical therapy plus surgical revascularization just have not
been compared in a prospective randomized fashion and without
these data it is difficult to know whether the difference in outcome
is due to differences in method of intervention, or differences in
patient selection, or a combination of those factors. Certainly, the
most recent publication of preliminary results from the Angio-
plasty and STent for Renal Artery Lesions (ASTRAL trial) show no
difference in renal function, blood pressure control, or adverse
cardiovascular events for percutaneous intervention and it has been
difficult to demonstrate any improvement in dialysis-free survival
for percutaneous intervention vs surgery. Matt Corriere of our
group is going to give a more in-depth discussion of our approach
to percutaneous intervention and some of our recent outcomes
later this morning, so I will defer a discussion of our selection
criteria and utilization of therapy to his comments later in this
morning’s program.
